New analysis shows high mortality and financial burden for pulmonary disease due to non-tuberculosis mycobacterium (NTM)

The first European study into the burden of non-tuberculosis mycobacterium pulmonary disease (NTM-PD), published recently in the European Respiratory Journal, has revealed that both the 3-year all-cause mortality rate and financial burden for patients with the disease is almost four times higher than a matched control group.
The study compared 125 newly diagnosed NTM-PD patients with 1250 control patients matched by age, gender and Charlson Comorbidity Index*over a period of 39 months. During this time period the all-cause mortality rate for those diagnosed with NTM-PD was 22.4%, almost four times higher than the matched control group (6%) (P<0.001). In the same observation period, the all-cause mortality rate in COPD patients who had NTM-PD was 41.5% (27/65 patients) but was only 15.9% (62/390) in COPD patients without NTM-PD (P<0.001).
NTMs represent a risk of infection for susceptible individuals – these are often patients with a predisposing chronic pulmonary disease, such as COPD or bronchiectasis. For these patients, the symptoms of the underlying disease overlap with the non-specific symptoms of NTM-PD, often leading to correct diagnosis often only being made at a late stage.
Source :      2017/5/11 12:36

خانه چاپ ارسال به دوستان نسخه متنی کوچک کردن متن بزرگ کردن متن دانلود خروجی پی دی اف خروجی میکروسافت ورد
0/10 (تعداد آرا 0 نفر )
Copyright © 2011 AASM. All Rights Reserved.